Company intelligence / Profile preview
CEAMED
Spainceamedsa.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
CEAMED develops small molecule inhibitors targeting STAT3 for oncology applications. Their lead compound CM‑978 shows potent inhibition of IL‑6 activated STAT3 with promising pharmacokinetics and low toxicity in animal models. The company has proposed its compounds as candidates for both triple negative breast cancer and as potential treatments to mitigate the cytokine storm associated with COVID‑19
- Therapeutic areas
- Infectious DiseasesOncology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Seeking collaborators/partners for further development
Beyond the preview
Go deeper on CEAMED.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CEAMED.